New radioactive tracer aims to illuminate hidden prostate cancer
Diagnosis
Ongoing
This early-phase trial tests TRDC002, a radioactive tracer that attaches to PSMA proteins on prostate cancer cells, to improve PET/CT imaging in patients whose cancer has returned or spread. Six adults with PSMA-positive recurrent or metastatic prostate cancer will receive a sing…
Phase: PHASE1 • Sponsor: C Ray Therapeutics • Aim: Diagnosis
Last updated Jun 27, 2026 12:07 UTC